HVSEN BIOTECHNOLOGY CO., LTD. |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 14.05 CNY | +0.64% |
|
-1.20% | -2.84% |
| 25/04 | Hvsen Biotechnology Co., Ltd. Proposes Final Cash Dividend for 2023 | CI |
| 24/04 | Hvsen Biotechnology Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
| Sales 2024 * | 1.25B 172M 14.36B | Sales 2025 * | 1.57B 216M 18.04B | Capitalization | 2.3B 317M 26.47B |
|---|---|---|---|---|---|
| Net income 2024 * | 67M 9.25M 772M | Net income 2025 * | 155M 21.41M 1.79B | EV / Sales 2024 * | 1.84 x |
| Net cash position 2024 * | - 0 0 | Net cash position 2025 * | - 0 0 | EV / Sales 2025 * | 1.47 x |
| P/E ratio 2024 * |
34.7
x | P/E ratio 2025 * |
15.1
x | Employees | 957 |
| Yield 2024 * |
0.43% | Yield 2025 * |
3.02% | Free-Float | 40.11% |
More Fundamentals
* Assessed data
More news
| 1 day | +0.64% | ||
| 1 week | -1.20% | ||
| Current month | +3.77% | ||
| 1 month | +3.77% | ||
| 3 months | +16.79% | ||
| 6 months | -4.10% | ||
| Current year | -2.84% |
1 week
13.81
14.87
1 month
11.6516.49
Current year
7.6116.49
1 year
7.6118.50
3 years
7.6152.40
5 years
7.6158.66
10 years
7.6158.66
| Managers | Title | Age | Since |
|---|---|---|---|
Kai Jie Yang
CEO | Chief Executive Officer | 54 | 01/14/01 |
Jian Zhou
CHM | Chairman | 50 | 01/09/01 |
Jie Liu
BRD | Director/Board Member | 60 | 01/12/01 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Huo Bao Xie
BRD | Director/Board Member | 56 | 10/16/10 |
Wei Yuan Zhang
FOU | Founder | 55 | 25/02/25 |
Zhen Ling Zeng
BRD | Director/Board Member | 61 | 10/16/10 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 30/24/30 | 14.05 | +0.64% | 1,683,200 |
| 29/24/29 | 13.96 | -0.71% | 1,779,700 |
| 26/24/26 | 14.06 | -1.68% | 2,530,736 |
| 25/24/25 | 14.3 | -1.79% | 2,772,890 |
| 24/24/24 | 14.56 | +2.18% | 1,945,545 |
End-of-day quote Shenzhen S.E., April 30, 2024
More quotes
Wuhan Hvsen Biotechnology Co Ltd is a China-based company mainly engaged in the research, development, production and sales of veterinary drugs, feed and additives. The Companyâs main products include veterinary active pharmaceutical ingredients, veterinary chemical preparations, veterinary traditional Chinese medicine preparations, feed and additives and environmental improvers, such as tyvanicin tartrate, florfenicol powder, banqing granules and piglet composites pre-mixed feed, etc. The Company mainly conducts its businesses in the China market.
Sector
Pharmaceuticals
Calendar
15/05/2024
- Annual General Meeting
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
BUY
Number of Analysts
2
Last Close Price
14.05
Average target price
-
EPS Revisions
Annual profits - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| -2.84% | 317M | |
| -9.60% | 6.48B | |
| +24.75% | 3.7B | |
| -3.20% | 3.1B | |
| +2.53% | 1.44B | |
| -15.13% | 1.37B | |
| -25.63% | 1.24B | |
| -6.64% | 1.19B | |
| -10.84% | 1.17B | |
| -.--% | 1.05B |
- Stock Market
- Equities
- 300871 Stock
